- cafead   Nov 10, 2022 at 10:42: AM
via The FDA was pretty clear a year and a half ago that BrainStorm Cell Therapeutics’ amyotrophic lateral sclerosis (ALS) therapy was not ready for prime time—but perhaps this latest rejection will really send the message home.
article source
article source